Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOPHO-DBH AML 2012 Protocol
2012-002934-35Phase 3Active
- Sponsor
- Region Västra Götaland
- Start
- Oct 2012
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of fludarabine, daunorubicin, cytarabine, mitoxantrone and etoposide in acute myeloid leukemia (AML) (2 arms), sponsored by Region Västra Götaland. Primary endpoint: MRD response after first induction. Started Oct 2012; status: active.
02
Drugs
fludarabinedaunorubicincytarabinemitoxantroneetoposide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2012-002934-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002934-35.